SC0191 / WuXi AppTec, Shijiazhuang Sagacity, Wuxi Biocity - LARVOL DELTA

Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. (PubMed, Int J Mol Sci) - "Adavosertib's clinical promise was challenged by inter-individual variations in response and side effects. Because of these promising preclinical outcomes, other WEE1 kinase inhibitors (Azenosertib, SC0191, IMP7068, PD0407824, PD0166285, WEE1-IN-5, Zedoresertib, WEE1-IN-8, and ATRN-1051) are being developed, with several currently being evaluated in clinical trials or as an adjuvant to chemotherapies...Reliable predictors of clinical responses based on mechanistic insights remain an important unmet need. Herein, we review the role of WEE1 inhibition therapy in breast cancer."

Journal • Review • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDC25C • CDK1 • CDK2 • GNRP • PKMYT1 • STING

WEE1 as a therapeutic target in TP53 and ARID1A concurrent mutant colorectal cancers (AACR 2025) - P2 | "Notably, ARID1A knockout sensitizes TP53-mutant, but not TP53-wildtype CRC cell lines, to WEE1 inhibitor MK-1775 or ZN-c3...These studies paralleled a phase 1b/2 clinical trial with SC0191 (a novel WEE1 inhibitor) based combination therapy in a cohort of late-line metastatic CRC patients (NCT06363552)...In conclusion, our research showed that targeting WEE1 is effective in TP53 and ARID1A mutant colorectal cancers. This therapeutic strategy is being tested in a phase 2 study for mCRC patients."

Colorectal Cancer • Oncology • Solid Tumor • ARID1A • TP53 • WEE1

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Tianshu Liu

Combination therapy • Metastases • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=112 | Not yet recruiting | Sponsor: Biocity Biopharmaceutics Co., Ltd.

Metastases • New P1/2 trial • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

[VIRTUAL] Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase. (ASCO 2020) - "Moreover, SC0191 oral administration showed significant antitumor efficacy which was better than AZD1775, in the NCI-H446 and BxPC-3 CDX mouse models, respectively. A novel Wee1 inhibitor, SC0191, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, and represents a promising clinical candidate for treating solid tumors, such as SCLC and PC. Research Funding: Sagacity"

Preclinical • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer • CDK1 • TP53